182541 Aromatase Inhibitor II, Letrozole - CAS 112809-51-5 - Calbiochem

182541
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
Demander le prix
Disponibilité limitéeDisponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service
      Voir les Prix & la Disponibilité
      Click To Print This Page

      Aperçu

      Replacement Information

      Tableau de caractéristiques principal

      Empirical FormulaCAS #
      C₁₇H₁₁N₅ 112809-51-5

      Prix & Disponibilité

      RéférenceDisponibilité Conditionnement Qté Prix Quantité
      182541-25MG
      Récupération des données relatives à la disponibilité...
      Disponibilité limitéeDisponibilité limitée
      En stock 
      Interrompu(e)
      Disponible en quantités limitées
      Disponibilité à confirmer
        Pour le restant : Nous vous tiendrons informé
          Pour le restant : Nous vous tiendrons informé
          Nous vous tiendrons informé
          Contacter le Service Clients
          Contact Customer Service

          Flacon en verre 25 mg
          Prix en cours de récupération
          Le prix n'a pas pu être récupéré
          La quantité minimale doit être un multiple de
          À la validation de la commande Plus d'informations
          Vous avez sauvegardé ()
           
          Demander le prix
          Description
          OverviewAn orally bioavailable non-steroidal triazole compound that acts as a potent and selective inhibitor of aromatase (IC50 = 140, 350 and 450 pM in Dex-treated fibroblasts, MCF-7Ca, and JEG-3 cells, respectively). Competitively, but reversibly binds to the heme iron of aromatase. Does not affect the synthesis of adrenal mineralocorticoid or glucocorticoids. Reported to be highly effective as an anti-estrogenic and anti-proliferative agent in estrogen-rich tumors. Also delays the fusing of the growth plates in adolescents and enhances the effectiveness of growth hormone. Shown to synergistically induce apoptosis and cause tumor regression when combined with IGF-1R inhibitors.
          Catalogue Number182541
          Brand Family Calbiochem®
          Synonyms4,4ʹ-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile, 1-(bis-(4-Cyanophenyl)methyl)-1,2,4-triazole
          References
          ReferencesHou, X., et al. 2011. Cancer Res. 71, 7597.
          Lisztwan, J., et al. 2008. Breast Cancer Res. 10, R56.
          Miller, W.R., et al. 2002. Cancer Invest. 20 (Suppl 2), 15.
          Long, B.J., et al. 1998. J. Steroid Biochem. Molec. Biol. 67, 293.
          Product Information
          CAS number112809-51-5
          FormWhite powder
          Hill FormulaC₁₇H₁₁N₅
          Chemical formulaC₁₇H₁₁N₅
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Purity≥99% by HPLC
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          FDS

          Titre

          Fiche de données de sécurité des matériaux (FDS) 

          Certificats d'analyse

          TitreNuméro de lot
          182541

          Références bibliographiques

          Aperçu de la référence bibliographique
          Hou, X., et al. 2011. Cancer Res. 71, 7597.
          Lisztwan, J., et al. 2008. Breast Cancer Res. 10, R56.
          Miller, W.R., et al. 2002. Cancer Invest. 20 (Suppl 2), 15.
          Long, B.J., et al. 1998. J. Steroid Biochem. Molec. Biol. 67, 293.
          Fiche technique

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision27-June-2012 JSW
          Synonyms4,4ʹ-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile, 1-(bis-(4-Cyanophenyl)methyl)-1,2,4-triazole
          DescriptionAn orally bioavailable non-steroidal triazole compound that acts as a potent and selective inhibitor of aromatase (IC50 = 140, 350 and 450 pM in Dex-treated fibroblasts, MCF-7Ca, and JEG-3 cells, respectively). Competitively, but reversibly binds to the heme iron of aromatase. Does not affect the synthesis of adrenal mineralocorticoid or glucocorticoids. Reported to be highly effective as an anti-estrogenic and anti-proliferative agent in estrogen-rich tumors. Also delays the fusing of the growth plates in adolescents and enhances the effectiveness of growth hormone. Shown to synergistically induce apoptosis and cause tumor regression when combined with IGF-1R inhibitors.
          FormWhite powder
          Intert gas (Yes/No) Packaged under inert gas
          CAS number112809-51-5
          Chemical formulaC₁₇H₁₁N₅
          Structure formulaStructure formula
          Purity≥99% by HPLC
          SolubilityDMSO (50 mg/ml; clear, colorless solution) or Ethanol (< 5 mg/ml; partially soluble)
          Storage +2°C to +8°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Toxicity Standard Handling
          ReferencesHou, X., et al. 2011. Cancer Res. 71, 7597.
          Lisztwan, J., et al. 2008. Breast Cancer Res. 10, R56.
          Miller, W.R., et al. 2002. Cancer Invest. 20 (Suppl 2), 15.
          Long, B.J., et al. 1998. J. Steroid Biochem. Molec. Biol. 67, 293.